ALK is devoted to improving the lives of people with allergies by developing pharmaceutical products that target the cause of allergy.
ALK is a world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction. Allergy vaccination is traditionally administered as subcutaneous injections or sublingual droplets. ALK aims to extend the use of allergy vaccination by introducing convenient, tablet-based vaccines, thereby offering many more patients a causal allergy treatment.
ALK has more than 1,700 employees with subsidiaries, production facilities and distributors worldwide. The company is headquartered in Hørsholm, Denmark and listed on the OMX Nordic Exchange Copenhagen.
ALK-Abelló Ltd abides by the ABPI Code of Practice.